4.7 Article

A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1)

Journal

JOURNAL OF NANOBIOTECHNOLOGY
Volume 19, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s12951-021-01063-4

Keywords

ROC1; Neddylation; siRNA-loaded nanomedicine; Photothermal therapy; Targeted delivery

Funding

  1. Shanghai Natural Science Foundation [20ZR1459100]
  2. Shanghai Key Clinical Specialty Construction Project [SHSLCZDZK03701]
  3. health commission of Pudong new area [PW2019E-1]

Ask authors/readers for more resources

The study introduces a folic acid-modified photothermal therapy nanomedicine capable of selectively delivering siRNA to liver cancer cells via receptor-mediated endocytosis and releasing them in a controlled manner triggered by pH. This genetic nanomedicine not only inhibits liver cancer cell proliferation and promotes liver cell apoptosis, but also shows superior growth inhibition of liver cancer when combined with photothermal therapy.
Knocking down the oncogene ROC1 with siRNA inhibits the proliferation of cancer cells by suppressing the Neddylation pathway. However, methods for delivering siRNA in vivo to induce this high anticancer activity with low potential side effects are urgently needed. Herein, a folic acid (FA)-modified polydopamine (PDA) nanomedicine used in photothermal therapy was designed for siRNA delivery. The designed nanovector can undergo photothermal conversion with good biocompatibility. Importantly, this genetic nanomedicine was selectively delivered to liver cancer cells by FA through receptor-mediated endocytosis. Subsequently, the siRNA cargo was released from the PDA nanomedicine into the tumor microenvironment by controlled release triggered by pH. More importantly, the genetic nanomedicine not only inhibited liver cancer cell proliferation but also promoted liver cell apoptosis by slowing ROC1 activity, suppressing the Neddylation pathway, enabling the accumulation of apototic factor ATF4 and DNA damage factor P-H2AX. Combined with photothermal therapy, this genetic nanomedicine showed superior inhibition of the growth of liver cancer in vitro and in vivo. Taken together, the results indicate that this biodegradable nanomedicine exhibits good target recognition, an effective pH response, application potential for genetic therapy, photothermal imaging and treatment of liver cancer. Therefore, this work contributes to the design of a multifunctional nanoplatform that combines genetic therapy and photothermal therapy for the treatment of liver cancer.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available